• Biotechnology company BiondVax has entered into a collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) to develop innovative NanoAbs
• BiondVax enjoys an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder the RCA
• The company recently announced intent to develop innovative NanoAbs targeting immune system cytokines such as IL-17 for the potential treatment of psoriasis and psoriatic arthritis
• Analysts at Zacks Small-Cap Research laud the shift in focus to anti-IL-17 and have pegged the stock to reach $8 per share from current levels of below $2 per share

Last September, a joint steering committee comprising professionals from BiondVax Pharmaceuticals (NASDAQ: BVXV), the Max Planck Institute for Multidisciplinary Sciences (“MPG”), and the University Medical Center Göttingen (“UMG”), made a decision. Established to guide the BVXV-MPG-UMG NanoAb collaboration, the committee decided to focus the nanosized antibody (“NanoAb”) development on other therapeutic indications in addition to COVID-19. This renewed focus would begin with the development of NanoAbs targeting immune system cytokines such as IL-17 (IL-17A, IL-17F, and IL-17A/F) for the potential treatment of psoriasis and psoriatic arthritis and IL-13 for the potential treatment of asthma (https://ibn.fm/AFw7N).

The committee’s decision is anchored in a five-year definitive research collaboration agreement (“RCA”) entered between BVXV, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, and its collaborators, MPG and UMG, allowing the company to exercise an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder (https://ibn.fm/m9LCk).

BiondVax’s decision to focus on developing additional NanoAb therapies was featured in new updated coverage by Zacks Small-Cap Research (https://ibn.fm/mIODn). The research report highlighted the company’s recent announcement regarding its intention to exercise the option to obtain an exclusive license to NanoAbs targeting IL-17 and other system cytokines. This announcement aligns with the company’s de-risked strategy, which includes pursuing biobetter drugs for against biological targets that are already proven to exert beneficial clinical results in humans when treated with conventional monoclonal antibodies (“mAbs”). Additionally, and in line with this strategy, the company intends to capitalize on NanoAbs’ status as potential “bio-betters” that offer potential advantages over mAbs, given their stability, extremely high binding affinity with effective neutralization, and high specificity.

The company has so far gathered significant data about the potential efficacy and capabilities of NanoAbs, thanks to its preclinical in vivo proof-of-concept study evaluating the effect of its inhaled anti-COVID-19 NanoAb therapy. The study, which utilized the industry-standard Syrian hamster model of SARS-CoV-2 infection, showed that the therapy virtually eliminated the virus from the lungs (https://ibn.fm/OHouD), caused milder and shorter illness (https://ibn.fm/nYkMP), and had prophylactic properties (https://ibn.fm/EyuhQ). Based on these encouraging findings, BiondVax is evaluating plans to commence a Phase 1/2a clinical trial, albeit with a keen eye on the mutation of the virus and the emergence of new variants of concern (“VoCs”).

The Zacks report lauds the shift to focus on the anti-IL-17 NanoAb as a “good decision.” By announcing its intention to exercise the option for an additional NanoAb, BiondVax is expanding its pipeline potential while mitigating certain risks to its business and diversifying its portfolio of possible block buster therapies.

Meanwhile, BVXV released its financial results for the first quarter of 2023, reporting cash and cash equivalents of $10.9 million, which analysts at Zacks estimate are sufficient to fund the company’s operations through the first quarter of 2024. An astute business practitioner as well as biotech innovator, BiondVax aims to maximize assets and increase revenues by offering its state-of-the-art cGMP manufacturing services to interested parties which could easily engender new strategic alliances as well as bolster the bottom line.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• U.S.-based gene therapy developer Genprex, Inc. is dedicated to finding more effective and novel solutions for battling cancer (particularly lung cancers) and diabetes
• Genprex utilizes a propriety platform that encapsulates tumor-suppressing genes within lipid nanoparticles that are injected intravenously
• The company has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for its two non-small cell lung cancer (“NSCLC”) programs using its drug candidate, REQORSA(R)
• Genprex also expects to begin a third trial using its REQORSA therapy against small cell lung cancer (“SCLC”) later this year
• The company recently used its proprietary nanoparticle delivery system, Oncoprex(R), in pre-clinical testing against immunotherapy-resistant tumors, reporting success with a different gene than the one in use for the Fast Tracked programs, thus showing early viability for the use of the Oncoprex platform with a second tumor suppressor gene
• Genprex’s chief medical officer discusses the developments in a new video released by the company May 23

Clinical-stage gene therapy developer Genprex (NASDAQ: GNPX) is expanding the breadth of its drug candidate potential with positive results from a preclinical study that examines the anti-tumor immune response of a gene believed to play a key role in suppressing certain tumors.

Genprex’s lead drug candidate, REQORSA immunogene therapy, uses Genprex’s proprietary, non-viral ONCOPREX Nanoparticle Delivery System to introduce the tumor-suppressing TUSC2 gene through an intravenous injection into cancer patients.

REQORSA is being evaluated in two clinical trials for non-small cell lung cancer (“NSCLC”) patients, and has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”). A third trial for small cell lung cancer (“SCLC”) will begin enrollment this year.

Genprex recently reported positive results from a study using its non-viral ONCOPREX(R) Nanoparticle Delivery System but substituting the NPRL2 gene for the TUSC2 gene (https://ibn.fm/ioHH9).

NPRL2 has long been regarded as a tumor-suppressing gene with potential value in the fight against lung cancers (https://ibn.fm/CyM9u). Genprex’s preclinical study examined the ability to introduce NPRL2 using the ONCOPREX platform into humanized mouse models and to inhibit tumor growth.

“The whole point of our oncology program is to identify tumor suppressor genes, which are systematically deleted during cancer development, and then re-express the tumor suppressor genes in cancers. This process has shown preclinically that it can achieve strong efficacy and is currently being evaluated in Phase 1/2 clinical trials of REQORSA,” Berger said (https://ibn.fm/5c9tg). “Now researchers have replicated that process in in vitro studies with the NPRL2 gene, which we believe is validation that ONCOPREX as a platform may be used with multiple tumor suppressor genes to address multiple types of cancer.” 

The NPRL2 study targeted mouse xenografts KRAS/STK11 mutant anti-PD1 resistant metastatic human non-small cell lung tumors. PD1 is an immune checkpoint that can help tumors resist immunotherapy, thereby promoting tumor progression despite treatment (https://ibn.fm/qCWaC). By successfully using the ONCOPREX delivery system with NPRL2 to target the anti-PD1 resistant tumor cells, these new preclinical data suggest that this could be a new way to treat lung cancer patients progressing on anti-PD1 treatment.

Genprex is developing a gene therapy drug candidate pipeline to battle cancers through its non-viral platform and has a second program to treat Type 1 and Type 2 diabetes using a viral vector.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Fr8Tech’s management recently shared its updated 2023 revenue guidance of $25-30 million, representing as much as nearly 20% growth from the previous year’s full-year revenue
• The growth will be fueled, in part, by the uptake of its services, with the company having posted the highest monthly increase in new client sign-ups since the launch of the Fr8App platform
• Following the recent 10 to 1 reverse share split necessary for Fr8Tech to regain Nasdaq compliance, the company showed that the price would need to show 11x growth on the closing price of March 28, 2023 to meet with third party forecasts for the company
• Fr8Tech remains committed to revolutionizing cross-border shipping, and the recent increase in new client sign-ups is indicative of the building momentum, and potential of its products and services

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company on a mission to revolutionize cross-border shipping by offering carriers increased growth opportunities and shippers with flexibility, visibility, and simplicity, is working hard to have its best year yet. The company’s management recently updated its 2023 revenue guidance of $25-30 million, representing up to nearly 20% growth from the previous year’s full-year revenue (https://ibn.fm/XvYo4) in a very difficult freight market.

This growth will be fueled, in part, by the uptake of its services, with the company having posted the highest monthly increase in new clients since the launch of its Fr8App platform. According to Fr8Tech’s Sales Director, Harry Martin, the new sign-ups were expected to yield a recurring monthly income of over $1 million a month, with the figure expected to start growing in Q2 and through the rest of the year.

“We have onboarded new clients in a variety of sectors, including automotive, beverage, motorcycles, and consumer goods that we had been working on for some time,” noted Mr. Martin.

“The new shipper clients represent a potential for significant recurring traffic on our platform and include leading first-tier automotive clients,” he added.

On March 7, 2023, Fr8Tech announced quarterly revenue for Q4 2022 amounting to $4.4 million. The company also reported a year-to-date (“YTD”) 2022 revenue of an impressive $25.9, representing a 20.6% growth from the previous year. Its management is optimistic that the current momentum will be maintained, yielding even more significant growth as time progresses and more value for its shareholders.

This performance will be very welcome, particularly following the recent 10 to 1 reverse share split necessary for Fr8Tech to regain Nasdaq compliance. As of the close of market on March 31, 2023, this share split saw the share price stand at $1.560, a 92.2% discount to independent analysts’ target price for the company’s ordinary shares of $20 per share on a split-adjusted basis. On the upside, it implied an over 11x growth on the closing price of March 28, 2023.

Fr8Tech remains committed to revolutionizing cross-border shipping, and the recent increase in new client sign-ups indicates the building momentum and potential of its products and services. As it looks forward to a successful year 2023, Fr8Tech continues to strengthen its brand, bolster its offerings, and increase incentives toward its customers. It is a company committed to its mission, taking on a once-complex process of international over-the-road shipping and simplifying it for the ordinary customer.

For more information, visit the company’s website at www.Fr8Technologies.com, and its freight matching platform information site at www.Fr8.App.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

• The graphite supply chain is geographically concentrated with nearly 65% of output currently produced in China
• The U.S. pursued to promote further investment and geographical diversification within the sector, with credits granted to electric vehicles produced with critical minerals that are not supplied by ‘foreign entities of concern’
• Reflex Advanced Materials are working towards demonstrating the positive economics of the past producing, Ruby Graphite mine in Montana, USA
• The company recently revealed that they are in talks with prospective North American customers and are beginning the material qualification programs for end use potential offtake clients down the line

A battery’s anode is a crucial component of its design, responsible for receiving incoming electricity and dissipating the heat created in the process of doing so; notably, it is also almost entirely made up of graphite. Today, the world is almost entirely dependent on China for its graphite supply – the nation mines 65% of the world’s graphite, processes 85 percent and is home to the world’s sixth largest anode material producers, according to the International Energy Agency (https://ibn.fm/58toQ). Mozambique is the world’s second largest producer of the mineral, set to account for nearly 14% of global supply by 2030 according to Benchmark Minerals; nevertheless, 96% of Mozambican graphite is mined from the country’s Cabo Delgado province, a geographical territory that has seen a huge rise in insurgent activity since 2017 (https://ibn.fm/5SBqe). With the natural graphite demand set to treble over the next four years as sales of electric vehicles soar, the constrained nature of the western supply chain of the essential mineral is becoming increasingly apparent.

The U.S. predominantly uses synthetic graphite, a material largely produced from the by-products of the fossil fuel industry within its domestic battery manufacturing industry. Paradoxical to its use in powering electric vehicles, aimed towards ultimately reducing greenhouse gas emissions, synthetic graphite is derived from a feedstock consisting of petroleum coke or pitch coke – the latter, a by- product resulting from coal tar with a carbon footprint nearly four times higher than that generated by mining natural graphite.

The U.S. has sought to tackle the growing conundrum posed by the geographical concentration of natural graphite mining through the passing of the recent Inflation Reduction Act (“IRA”). The legislation states that EVs entering the market after 2024 will not be eligible for tax credits – which can go up to $7,500 – if any of the critical minerals are extracted, processed or recycled by a “foreign entity of concern”, which includes China. However, and as a result, graphite prices have soared by nearly 60% since the start of 2022 with the World Bank Group now predicting that a rise in anode demand will likely fuel a material shortage of 8 million tonnes by 2040.

Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF), a British Columbia-based strategic minerals company focused on locating and developing economic properties within the advanced materials space, has centred its corporate mission around catering to the burgeoning need for natural graphite supply through its flagship asset the Ruby Graphite Project. One of a handful of companies comprising the western natural graphite supply chain, Reflex Advanced Material’s flagship project is a past producing graphite mine in southwest Montana which produced upwards of 2,400 tons of graphite between 1902 and 1948, as well as the Ontario-based Zig Zag Lithium Property, encompassing eight mining claims across 2,710 hectares.

As a result, and in a sector characterized by opaque pricing and long-term bilateral off-take agreements between producers and consumers, Reflex Advanced Materials recently revealed that it has begun the qualification process with prospective North American customers, putting the company years ahead of their peers within the lengthy graphite sales cycle. With an upcoming drill program scheduled to kick-off in the summer of 2023 at its Ruby Graphite project in Montana, alongside two product development and material research partnerships currently underway in an effort to help the company diversify its risk profile and improve margins, Reflex Advanced Materials are aiming to emerge as one of the biggest beneficiaries of the global push towards an electric vehicle-powered future.

For more information, visit the company’s website at www.ReflexMaterials.com.

NOTE TO INVESTORS: The latest news and updates relating to RFLXF are available in the company’s newsroom at https://ibn.fm/RFLXF

• XESP’s managed service offering drives growth through its proprietary smart technology stack, the Digital Engagement Engine(TM)
• This technology allows complete control of content while optimizing reach and lift
• XESP’s ‘Growth as a Service’ allows clients to focus on their brands, core product offerings, and content creation

B2B businesses have seen an increased demand for digital assistance, especially for customer-driven marketing and associated communications. Electronic Servitor Publication Network (OTCQB: XESP), a digital engagement and activation company, offers a managed service that provides digital engagement and activation solutions for companies seeking to enhance their growth. The company is changing the landscape of digital marketing for its clients with its proprietary technology, the Digital Engagement Engine(TM).

XESP’s managed service is powered by a proven and proprietary technology, utilizing a combination of automation, unique data management, and a modern workflow built on a microservices architecture. It provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, combining digital experiences that accelerate an audience from awareness to action. The result is greater reach and lift for client content.

XESP’s ‘Growth as a Service’ offering is designed to allow clients to focus on their brands, core product offerings, and content creation, while XESP manages the technology and outcome. The Digital Engagement Engine(TM) is not just another marketing or technology tool but a way to develop real connections with target markets.

For more information, visit the company’s website at www.XESPN.com. 

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• The partnership will leverage D-Wave’s Leap(TM) quantum cloud service coupled with IPG’s data assets
• IPG recently launched a pilot program with D-Wave to build marketing optimization equations for one of the company’s top 20 clients in the retail industry
• Leap provides access to the Advantage quantum computing system and quantum hybrid solvers, enabling users to tackle complex problems of up to 1 million variables and 100,000 constraints

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services focused on delivering customer value via practical quantum computing solutions, recently announced a partnership with one of the world’s leading global advertising and marketing services companies, Interpublic Group (NYSE: IPG). Through the partnership, D-Wave and IPG will work together on quantum computing applications that fuel innovation in marketing investments and strategies (https://ibn.fm/fYyy3).

As part of their collaboration, D-Wave and IPG will use D-Wave’s quantum computers and hybrid solvers through the Leap cloud service, coupled with IPG’s data assets, creating quantum applications designed to build high-value audiences for marketers in various settings. IPG recently launched a pilot program with D-Wave to build marketing optimization equations for one of the company’s top 20 clients to optimize campaigns in the retail industry.

D-Wave’s Leap quantum cloud service delivers immediate, real-time access to the company’s Advantage(TM) quantum computers and quantum hybrid solver service – allowing for enterprise-class performance and scalability (https://ibn.fm/waofR). Through a seamless and secure cloud-based connection, Leap users can easily start solving complex problems of up to 1 million variables and 100,000 constraints. By eliminating the need to wait hours, days, or even weeks for useful answers to industry problems, D-Wave is helping businesses accelerate solutions to their most challenging problems now.

D-Wave CEO Dr. Alan Baratz explained that consumers encounter brand messages daily, and breaking through to reach the right customer at the right time remains a difficult challenge for businesses, given the vast number of existing variables. “We’re excited to work with IPG to bring the power of quantum to advertising optimization, more efficiently harnessing a massive amount of data to create hyper-targeted campaigns that drive desired outcomes for brands,” Dr. Baratz added.

D-Wave has a portfolio of commercial clients, including blue-chip industry leaders like Volkswagen, Mastercard, Deloitte, ArcelorMittal, Siemens Healthineers, Unisys, Accenture, BBVA, NEC Corporation, Pattison Food Group Ltd., DENSO, and Lockheed Martin. During the first quarter of 2023, D-Wave signed several new and expanded existing customer engagements with Forbes 2000 companies and industry leaders, including IPG, Unisys US, POLARISqb, and Quantum Algorithms Institute.

IPG is an S&P 500 company, home to some of the world’s best-known and most innovative communication specialists. IPG brands include Acxiom, Craft, FCB, FutureBrand, Golin, Huge, Initiative, IPG Health, Jack Morton, Kinesso, MAGNA, Matterkind, McCann, Mediabrands, Mediahub, Momentum, MRM, MullenLowe Group, Octagon, R/GA, UM, Weber Shandwick, and more.

“At IPG, we understand that every customer is unique, with very personal passions, behaviors, and motivations,” said Philippe Krakowsky, CEO of IPG. “By working with D-Wave and adopting quantum technology as part of our tech stack, we believe we can uncover an even greater collection of data-driven insights to deliver more relevant and effective marketing for our clients at scale.”

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

• In May, Lexaria made a number of positive announcements related to its R&D initiatives
• In addition to holding its 2023 Annual Meeting, the company completed dosing for its human clinical nicotine study, NIC-H22-1
• Lexaria also reported 900% improvements in delivery of DehydraTECH(TM) processed estrogen into blood plasma in an animal study
• In a human hypertension study, the company announced that its DehydraTECH-CBD formulation resulted in significant reductions in the blood plasma levels of pro-inflammatory biomarkers (IL 8, 10, and 18)
• These biomarkers are linked to cardiovascular disease (“CVD”) and many other conditions, such as asthma, lung diseases, chronic kidney disease, fatty liver disease, Type 1 and 2 diabetes, obesity, and rheumatoid arthritis

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, held its 2023 Annual Meeting on the 9th of May, with shareholders voting on several agenda items, including the election of directors, appointment of auditors, approval of the stock option pricing, approval of the amendment to the maxim number of shares issuable pursuant to the Incentive Equity Plan, and approval of the addition of an evergreen formula to the Incentive Equity Plan. All items put to the vote were approved by the majority, setting the stage for what would become a month of even more positives, particularly around the company’s research and development (“R&D”) initiatives.

“If you’ve been following Lexaria for any period of time, you know that applied R&D is our lifeblood. It helps us establish areas of investigation for commercial pursuits, reduces risks of the unknown for both commercial and regulatory goals, and more,” wrote Lexaria CEO Chris Bunka in the January 2023 annual letter (https://ibn.fm/XQswm).

A look at the company’s announcements throughout May shows its unwavering resolve to support its lifeblood and, in the process, gain additional knowledge and understanding of the limitations and capabilities of its patented DehydraTECH(TM) technology. The company started the month off with the announcement that it had completed dosing in its human clinical nicotine study, NIC-H22-1.

With data showing that cigarette smoking claims the lives of more than 7 million people per year globally, Lexaria conducted the study as part of its efforts to validate its reduced-risk technology, which is poised to potentially provide tobacco smokers with a safer and faster-acting source of purified nicotine that delivers nicotine into blood plasma faster, potentially satisfying cravings more quickly. The study evaluated the capabilities of the company’s DehydraTECH-processed oral nicotine formulation by comparing it with the performance of other commercially available oral nicotine pouches sold under the On! and Zyn brands. Lexaria will provide further updates and any relevant material findings as they become available (https://ibn.fm/PYLeS).

Lexaria also reported the completion of its animal study HOR-A22-1, demonstrating its DehydraTECH(TM) platform technology significantly enhanced the oral delivery of estradiol, a type of estrogen hormone that is used in therapeutic products in women’s health sector (https://ibn.fm/HAL2x). Performed in 20 female Sprague-Dawley rats, the study compared a DehydraTECH-estradiol formulation to a generic estradiol composition.

The study aimed to evaluate the ability of DehydraTECH to enhance the delivery properties of the orally administered hormone using parameters such as Cmax, the maximum concentration in the bloodstream, and area under the curve (“AUC”), a measure that gives insight into the total delivery of estradiol over time and the extent of exposure to estrone. (Estrone is a second type of estrogen that is reversibly manufactured from estradiol in tissues found in the mammary gland, uterus, and liver.)

The animal study HOR-A22-1 found that the DehydraTECH-estradiol formulation resulted in a Cmax about 900% higher than the control formulation’s. Additionally, the AUC readings for estradiol and estrone when the DehydraTECH-processed composition was used were 1,500% and 12,500% higher, respectively, than when the control was used.

In other R&D, Lexaria announced additional findings from its human clinical study HYPER-H21-4, completed last year. The hypertension study sought to evaluate DehydraTECH-processed cannabidiol (“CBD”) as a potential antihypertensive medication and already achieved primary efficacy and safety objectives. According to the company, the study also demonstrated significant reductions in several pro-inflammatory biomarkers – interleukin (“IL”) 8, 10, and 18 – known to be linked to cardiovascular disease (“CVD”) and many other conditions such as asthma, lung diseases, chronic kidney disease, fatty liver disease, type 1 and 2 diabetes, obesity, and rheumatoid arthritis.

More specifically, after five weeks of treatment, the DehydraTECH-CBD formulation resulted in a 19%, 27%, and 43% reduction in the blood plasma levels of IL 8, 10, and 18, respectively. “There is some pre-clinical evidence for the anti-inflammatory actions of CBD, but this is likely the most convincing evidence in humans that I have ever seen,” Dr. Philip Ainslie, Cardiovascular Advisor to Lexaria and Lead Investigator of the study, said of the results.

In non-R&D-related news, the company reported the closing of its public offering, which generated approximately $2.0 million in gross proceeds (https://ibn.fm/CZgk2).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• The positive data from the Acclaim-1 Phase 1 portion of the Phase 1/2 clinical trial has been published in an abstract at the 2023 American Society of Clinical Oncology Annual Meeting, which took place in Chicago, IL and online June 2 – 6, 2023
• Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial evaluating REQORSA(R) in combination with Tagrisso(R)
• The Phase 2 expansion portion of the study is expected to enroll approximately 66 patients – half of which will have only received Tagrisso(R) and the other half receiving Tagrisso(R) and chemotherapy
• The global lung cancer treatment market is expected to grow to $48.7 billion by 2026

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that positive data from the Phase 1 portion of its Acclaim-1 clinical trial evaluating REQORSA(R) Immunogene Therapy in combination with Tagrisso(R) in late-stage non-small cell lung cancer (“NSCLC”) have been published in an abstract at the 2023 American Society of Clinical Oncology (“ASCO”) Annual Meeting, which took place June 2-6, 2023 at McCormick Place in Chicago, IL, and online (https://ibn.fm/tzmZS).

The preliminary results from eight patients show that the combination of REQORSA and Tagrisso was well tolerated at all three dose levels of the Phase 1 trial, with encouraging evidence of efficacy observed. “We are thrilled to have our abstract, which reports positive results from the Phase 1 portion of our Acclaim-1 clinical trial, published at the ASCO Annual meeting,” said Mark Berger, MD, Chief Medical Officer at Genprex. “We are encouraged by the favorable safety profile of REQORSA, as well as the preliminary efficacy data we have observed.  These data supported the Safety Review Committee’s approval of our advancement to the Phase 2 expansion portion of the clinical trial, which we expect to begin in the third quarter.”

The Acclaim-1 clinical trial is an open-label, multi-center Phase 1/2 clinical trial evaluating the company’s lead drug candidate in combination with Tagrisso in patients with late-stage NSCLC with activating epidermal growth factor receptor mutations whose disease progressed after treatment with Tagrisso. The dose escalation Phase 1 portion of the Acclaim-1 clinical trial has been completed, and the Phase 2 expansion portion of the study is expected to enroll approximately 66 patients, half of whom will have received only Tagrisso treatment – the other half will have received Tagrisso and chemotherapy treatments.

Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies to provide novel treatment approaches, which includes its lead product candidate REQORSA Immunogene Therapy. REQORSA consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules with a positive electrical charge. The drug candidate is injected intravenously and targets cancer cells.

Developing resistance to drugs like Tagrisso, Keytruda, and Tecentriq is inevitable for many cancer patients. In addition, the average five-year lung cancer survival rate is 18.6%, which highlights the importance of REQORSA’s potential in the global lung cancer industry, which is expected to grow to $48.7 billion by 2026 (https://ibn.fm/8Eqy0).

“It is encouraging that several patients whose disease was progressing on their previous therapy are now having long periods of response and stable disease in the Phase 1 portion of the study,:” said Rodney Varner, Chairman, President, and Chief Executive Officer of Genprex. “We wish to thank the patients and investigators participating in our clinical trials and our investors who make it possible to move our drug candidates forward toward regulatory approval for patients in need.”

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• XESP’s proprietary Digital Engagement Engine(TM) develops real connections with target markets, pointing to the future of growth for B2B organizations
• The Digital Engagement Engine(TM) is a sophisticated technology stack that does 1-to-1 contact analysis and 1-to-1 content provisioning making sure that the right audience is reached and that interactions are productive
• XESP’s offering is called “Growth as a Service” which provides fully managed digital services focused on enhancing growth for B2Bs

The digital landscape has transformed and evolved over the past few years – going from a focus primarily on SEO, to social media, content, and video marketing campaigns. Now, there are thousands of tactics being thrown on the drawing table being pushed by the latest digital marketing gurus – but none of these omnichannel marketing schemes are as effective as Electronic Servitor Publication Network (OTCQB: XESP) Digital Engagement Engine(TM). Not to be considered just a marketing tool, it’s a powerful new way to ensure real connections between clients and their target markets, and it represents the future of business growth.

XESP is a market disruptor for B2B companies, utilizing cutting-edge data analytics and smart technology to identify the needs within a given target market. The company can then tailor content to meet that market’s precise needs and deliver it to them exactly when needed. The company has coined this managed service as “Growth as a Service.”

Data is run through XESP’s Digital Engagement Engine(TM), which is a sophisticated technology stack that does 1-to-1 contact analysis and 1-to-1 content provisioning, making sure that communications are relevant, meaningful, and create a positive experience. XESP’s technology goes beyond omnichannel marketing, offering a way for those who want to reach their target markets right where they are, and create meaningful engagements that stay with them until they become valued customers.

XESP’s highly focused approach includes the following:

• Cutting-edge Data Analysis – smart tools and techniques to flawlessly acquire data
• Identification Tech Stack – identification of communities of interest within a target market
• Tailored Content – designed to attract and engage individuals within that target market
• Precision Delivery – drive customers to action by addressing their needs at the optimal moment…when they need it

XESP’s focus is to enhance growth through the effective application of technology and service for B2B organizations that are looking for a minimum of $10 million in additional growth. XESP’s managed service utilizes its technology to help businesses increase their presence in a way that surpasses the traditional omnichannel approach.

For more information, visit the company’s website at www.XESPN.com. 

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

Companies looking for alternative methods of raising capital and investors interested in overlooked breakout opportunities will find the annual Reg A Conference, hosted by DealFlow Events, an exciting event to conduct business and learn about the current market.

This year’s Reg A Conference will take place June 30 in New York’s luxurious Westchester Country Club, just a few minutes north of New York City.

This one-day gathering provides insight on marketing strategies, a review of the current capital-raise landscape, news about regulatory oversight and analysis of what has (and hasn’t) worked in recent Reg A transactions.

Our agenda for The Reg A Conference is now available at https://regaconference.com/agenda/. Besides panels and presentations from thought leaders such as Jonathan Stidd of DealMaker Reach, Nathaniel Dodson of Crowdfunding Lawyers, Dawson Russell of Capital Raise, Irene Hyder of One9 Strategy, and more, The Reg A Conference is known for giving attendees a networking experience they won’t find anywhere else.

New to this year’s conference is a dedicated space for scheduled one-on-one meetings between qualified companies and attendees looking for investment opportunities, banking relationships, or professional services. Prior to the event, all attendees will receive a program guide with tear sheets containing companies’ financial data and background information, enabling participants to set up 20-minute meetings with the companies of their choice using intuitive MeetMax software.

Throughout the day, the relaxed, open-air atmosphere of the Westchester Country Club will keep attendees refreshed and relaxed, so they are ready to seize the educational and networking opportunities this popular event has to offer.

Best of all, the whole experience is FREE to private and public companies considering or in the process of conducting Reg A transactions. If you plan on attending the event as an executive-level employee of a qualifying private or public company, visit https://regaconference.com/private-companies/ to receive your free ticket.

Things to know:

• Situated on New York’s eastern seaboard, proximate to New York City’s international financial capital
• Panelists and presenters focused exclusively on alternative financing for the Reg A marketplace; no fluff, no filler, just actionable information
• Insights on how Reg A works, timelines, fees, regulations and real-life activity
• Networking opportunities in one of the most prestigious country clubs in America, amid a relaxed atmosphere and space designed to facilitate the free flowing exchange of information
• Invited professionals including underwriter and issuer law firms, structured financial investors and Reg A investors, investor relations professionals, accountants, marketing consultants and fund managers
• One-on-one dedicated scheduling as a new feature to this annual event, powered by MeetMax software and company data statements

Behind the scenes:

DealFlow Events has hosted more than 200 events covering a range of financial topics during the last 20 years. Seasoned conference developers bring leading practitioners in each field together with major sponsors that service the respective markets.

DealFlow’s events take place in-person and virtually to provide access to all individuals working within their industries. The conference series has extended to international arenas, taking place in the United States, Europe, Asia, the Middle East, and Canada.

For more information about this event and to register, please visit https://ibn.fm/cGtaE.